<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006707</article-id><article-id pub-id-type="pmc">PMC11860291</article-id><article-id pub-id-type="doi">10.3390/vaccines13020160</article-id><article-id pub-id-type="publisher-id">vaccines-13-00160</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Analysis on the Epidemiological Characteristics of Breakthrough Varicella Cases and Incremental Effectiveness of 2-Dose Varicella Vaccine in China</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1133-2310</contrib-id><name><surname>Lin</surname><given-names>Mingzhu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="fn1-vaccines-13-00160" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Tian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="fn1-vaccines-13-00160" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Pengfei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Laibao</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="c1-vaccines-13-00160" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Caoyi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="c1-vaccines-13-00160" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Casuccio</surname><given-names>Alessandra</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00160">Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China; <email>mzlin@pdcdc.sh.cn</email> (M.L.); <email>tyang@pdcdc.sh.cn</email> (T.Y.); </aff><author-notes><corresp id="c1-vaccines-13-00160"><label>*</label>Correspondence: <email>lbyang@pdcdc.sh.cn</email> (L.Y.); <email>cyxue@pdcdc.sh.cn</email> (C.X.)</corresp><fn id="fn1-vaccines-13-00160"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>160</elocation-id><history><date date-type="received"><day>16</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>27</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background: A 2-dose varicella vaccination strategy has been implemented in Shanghai, China since 2018. This study aims to analyze the epidemiological characteristics of breakthrough varicella cases and to evaluate the incremental effectiveness of the 2-dose varicella vaccination among Chinese children. Methods: A retrospective investigation was conducted among native children born between 2015 and 2019 in the Pudong New area of Shanghai, China. From 2016 to 2023, demographic information and data regarding varicella vaccination were collected through the Shanghai Immunization Information System, while information on varicella infections was obtained from the China Information System for Disease Control and Prevention. The incremental vaccine effectiveness (VE) for varicella was defined as (1 &#x02212; relative risk (RR)) &#x000d7; 100%, where RRs were calculated based on the rate of varicella infections. Results: A total of 519,951 local children were enrolled in the cohort analysis. The overall rate of breakthrough varicella infections was found to be 0.25%, corresponding to 1182 cases. Specifically, the rates of breakthrough varicella infections for individuals who received 1-dose and 2-dose VarV were 0.39% (977 cases) and 0.10% (205 cases), respectively. The average ages of onset for these infections were 2.13 &#x000b1; 0.99 years and 5.52 &#x000b1; 1.18 years, respectively. Furthermore, the breakthrough varicella infection rate among individuals born between 2015 and 2019 exhibited a decline, decreasing from 0.52% to 0.26% for those who received one dose of VarV, and from 0.23% to 0.01% for those who received two doses. The VE against all varicella was 85% (95% confidence interval: 84&#x02013;86) for one dose and 96% (95% confidence interval: 96&#x02013;97) for two doses, and the incremental VE was 75% (95% confidence interval: 71&#x02013;79) compared with 1-dose. Conclusions: the 2-dose VarV vaccination strategy provided excellent protection to prevent varicella, and the universal 2-dose regimen of the varicella vaccine should be recommended to prevent varicella disease among children in China.</p></abstract><kwd-group><kwd>varicella</kwd><kwd>2-dose varicella vaccination strategy</kwd><kwd>varicella effectiveness</kwd><kwd>breakthrough varicella</kwd></kwd-group><funding-group><award-group><funding-source>the Key Discipline Program of Pudong New Area Health System</funding-source><award-id>PWZxk2022-25</award-id></award-group><award-group><funding-source>Shanghai Three-year Action Plan to Strengthen the Construction of Public Health System Excellent Academic Leader Project (2023&#x02013;2025)</funding-source><award-id>GWVI-11.2-XD08</award-id></award-group><award-group><funding-source>Shanghai Pudong New Area Science and Technology Development Fund Project</funding-source><award-id>PKJ2023-Y34</award-id></award-group><award-group><funding-source>Shanghai Pudong New Area Eagle Talent Program</funding-source><award-id>PDCDC-XY-2024-09</award-id></award-group><award-group><funding-source>Shanghai Pudong New Area Health System Outstanding Young Medical Talent Training Program</funding-source><award-id>PWRq2023-29</award-id></award-group><funding-statement>This research was supported by the Key Discipline Program of Pudong New Area Health System [Number: PWZxk2022-25], Shanghai Three-year Action Plan to Strengthen the Construction of Public Health System Excellent Academic Leader Project (2023&#x02013;2025) [Number GWVI-11.2-XD08], Shanghai Pudong New Area Science and Technology Development Fund Project [Number PKJ2023-Y34], Shanghai Pudong New Area Eagle Talent Program [Number PDCDC-XY-2024-09] and Shanghai Pudong New Area Health System Outstanding Young Medical Talent Training Program [Number PWRq2023-29].</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00160"><title>1. Introduction</title><p>Varicella, caused by the Varicella-zoster virus (VZV), is an acute, highly infectious disease that spreads primarily through respiratory droplets and direct contact. The typical symptoms include systemic papules and pruritic varicella rashes, which are common in children and can lead to serious complications, such as pneumonia, encephalitis and even death [<xref rid="B1-vaccines-13-00160" ref-type="bibr">1</xref>]. Contagiousness begins 1&#x02013;2 days before the onset of the disease and lasts until the rash has reached the dry and crusted stage, with transmission caused by exposure to air droplets from infected individuals [<xref rid="B2-vaccines-13-00160" ref-type="bibr">2</xref>]. The disease can occur in all seasons of the year, but is more prevalent in winter and spring [<xref rid="B3-vaccines-13-00160" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-13-00160" ref-type="bibr">4</xref>], which can easily cause clustered epidemics in schools and kindergartens [<xref rid="B5-vaccines-13-00160" ref-type="bibr">5</xref>].</p><p>Global data from the World Health Organization show that at least 1.4 billion new cases of varicella are reported annually, with 4.2 million cases resulting in serious complications and about 4200 deaths related to varicella [<xref rid="B6-vaccines-13-00160" ref-type="bibr">6</xref>]. Recent studies have shown that the number of VZV infections worldwide increased by 17.85% in 2019 compared to 1990 [<xref rid="B7-vaccines-13-00160" ref-type="bibr">7</xref>].The burden of disease caused by varicella is also high. A study in the United States found that varicella-related illness costs 90 million in medical costs per year and 4.39 billion in unemployment costs [<xref rid="B8-vaccines-13-00160" ref-type="bibr">8</xref>]. A study on the economic evaluation of varicella in Spain [<xref rid="B9-vaccines-13-00160" ref-type="bibr">9</xref>], analyzed from a social point of view, found that the total cost of varicella treatment was about 1.723 billion dollars over a 50-year period for unvaccinated individuals. In the absence of universal varicella vaccination, 31 European countries carried an annual economic burden of more than 6.6 billion euros [<xref rid="B10-vaccines-13-00160" ref-type="bibr">10</xref>].</p><p>The varicella vaccine (VarV) is the most effective way to prevent and control varicella [<xref rid="B11-vaccines-13-00160" ref-type="bibr">11</xref>]. The World Health Organization advises routine childhood immunization in countries experiencing a significant public health impact due to the disease [<xref rid="B1-vaccines-13-00160" ref-type="bibr">1</xref>]. In the United States, hospitalizations and outpatient visits to varicella patients decreased by 88% and 59%, respectively after the varicella vaccine was first included in the National Immunization Program (NIP) as a single-dose regimen between 1994 and 2012 [<xref rid="B12-vaccines-13-00160" ref-type="bibr">12</xref>]. In Brazil, a single dose of the varicella vaccine was introduced for children at 15 months of age in 2013, and three years later the rate of hospitalizations for varicella among the vaccinated population decreased by 47.6%. The varicella vaccine is 93% effective in preventing severe varicella and the average effectiveness of varicella prevention is 86% [<xref rid="B13-vaccines-13-00160" ref-type="bibr">13</xref>].</p><p>In 1998, China introduced the self-paid varicella vaccine [<xref rid="B14-vaccines-13-00160" ref-type="bibr">14</xref>], which is considered an effective measure to prevent and control the spread of the disease. Long-term epidemiological surveillance has shown that a certain proportion of breakthrough varicella cases may continue to occur after one dose of VarV vaccination in children, and the incidence rate shows an upward trend as vaccination time increases. For example, a 14-year follow-up study in California, USA, found that the average annual incidence of breakthrough varicella cases was 15.9 &#x02030; [<xref rid="B15-vaccines-13-00160" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-13-00160" ref-type="bibr">16</xref>]. In 2012, a 2-dose VarV immunization strategy was implemented in parts of China, demonstrating good protective effects. However, breakthrough cases of varicella still occurred [<xref rid="B15-vaccines-13-00160" ref-type="bibr">15</xref>]. The clinical symptoms of varicella breakthrough cases are usually mild [<xref rid="B17-vaccines-13-00160" ref-type="bibr">17</xref>], but can still be transmitted and cause varicella public health emergencies [<xref rid="B18-vaccines-13-00160" ref-type="bibr">18</xref>]. Different immunization strategies require different amounts of financial support, and the decision between one or two doses remains a key consideration. To better prevent varicella, Shanghai began to implement emergency vaccination with VarV at schools and kindergartens in 2014 [<xref rid="B19-vaccines-13-00160" ref-type="bibr">19</xref>]. In 2018, a vaccination strategy involving two free doses of VarV was implemented in Shanghai. There have been no studies on breakthrough cases of varicella in Shanghai so far. This study aims to analyze the epidemiological characteristics of varicella breakthrough cases after one and two doses of VarV in children born in Shanghai between 2015 and 2019. Additionally, it aims to examine the incremental effectiveness of 2-dose varicella vaccination among Chinese children, providing a reference for optimizing the strategy of VarV immunization.</p></sec><sec sec-type="methods" id="sec2-vaccines-13-00160"><title>2. Methods</title><sec id="sec2dot1-vaccines-13-00160"><title>2.1. Varicella Surveillance</title><p>Pudong New Area is located in the eastern part of Shanghai Municipality, China. With approximately 5.81 million residents, Pudong accounts for 20% of Shanghai&#x02019;s total population. The demographic characteristics in Pudong, such as age distribution, align with those of Shanghai, as indicated in the national census. Furthermore, since the disease surveillance system and immunization program in Pudong are implemented in accordance with the relevant regulations of Shanghai Municipality, the data presented in this study can serve as a reliable representation of the entire city. Since 2006, local health providers and physicians have been required to report varicella cases electronically through the China Information System for Disease Control and Prevention (CISDCP) within 24 h. A voluntary two-dose varicella vaccination schedule has been recommended in Shanghai, China, since November 2017 and was incorporated into the immunization program of Shanghai in August 2018. The vaccination records of children are maintained in the Shanghai Immunization Information System, which includes demographic and vaccination information.</p></sec><sec id="sec2dot2-vaccines-13-00160"><title>2.2. Varicella Vaccination</title><p>Shanghai began implementing emergency vaccinations with VarV in schools and kindergartens in 2014. Prior to 2018, one dose of the varicella vaccine was recommended for children aged 12 months in Shanghai. However, starting in August 2018, the two free doses of VarV are respectively administered at 12&#x02013;28 months of age and again at 4 years of age. Children born on or after 1 August 2014, are eligible for a free second dose of VarV after they reach 4 years of age, while those born before 1 August 2014, may receive a second dose of VarV for a fee.</p></sec><sec id="sec2dot3-vaccines-13-00160"><title>2.3. Data Sources</title><p>This study included local children born in the Pudong New Area of Shanghai from 2015 to 2019. Demographic information and varicella vaccination data for these children, covering the period from 2016 to 2023, were collected through the Shanghai Immunization Information System. Additionally, varicella infection information data were obtained from the China Information System for Disease Control and Prevention. It is important to note that during the collection of vaccination data, we included not only children who received vaccinations according to the routine schedule but also those who received their first dose of the varicella vaccine more than 12 months after births with a delay of up to 3 years. This particular group was included because our research aims to comprehensively analyze the association between the varicella vaccination history and the incidence of varicella. The vaccination status of these children provides more detailed information for the study, facilitating an in-depth exploration of the differences in varicella incidence associated with varying vaccination doses. All children included in the study were categorized based on the number of varicella vaccine doses they received. We separately recorded and analyzed the incidence of varicella in children who received only one dose compared to those who received two doses of the varicella vaccine, in order to evaluate the impact of different vaccination doses on the incidence of varicella.</p></sec><sec id="sec2dot4-vaccines-13-00160"><title>2.4. Definitions</title><p>Breakthrough varicella is defined as a case that develops more than 42 days after vaccination. The breakthrough infection rate is defined as the proportion of breakthrough infections among children who have received varicella vaccinations.</p></sec><sec id="sec2dot5-vaccines-13-00160"><title>2.5. Data Analysis</title><p>The basic characteristics were compared between the breakthrough cases of individuals who received one dose and those who received two doses, using Pearson&#x02019;s Chi-square test, Fisher&#x02019;s exact test or the Wilcoxon rank-sum test, as appropriate. The incremental vaccine efficacy (VE) was defined as (1 &#x02212; relative risk (RR)) &#x000d7; 100%, where RRs were calculated based on the breakthrough infection rates. Recipients of the one-dose vaccine served as the reference group for calculating incremental VE, which was defined as the additional protection conferred by the two-dose vaccination compared to the one-dose vaccination. Data were entered into Microsoft Excel 2010, and statistical analyses were performed using SPSS version 22.0. A <italic toggle="yes">p</italic> value of less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00160"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00160"><title>3.1. Population Description</title><p>Data on a total of 519,951 newborns in the Pudong New Area of Shanghai, born between 2015 and 2019, including demographic information and VarV vaccination information, were obtained from the Shanghai Immunization Information System, referred to as &#x0201c;Database A&#x0201d;. Within Database A, 54,517 children did not have varicella vaccination, 250,821 children had received 1-dose of VarV and 214,613 had received 2-dose of VarV. Additionally, 23,843 cases of varicella with onset dates ranging from 2016 to 2023 were obtained through the China Information System for Disease Control and Prevention, referred to as &#x0201c;Database B&#x0201d;. After matching Database A and B based on name, gender and date of birth, a total of 1182 breakthrough varicella cases were obtained, of which 977 cases received one dose of VarV, while 205 cases received two doses of VarV (<xref rid="vaccines-13-00160-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec3dot2-vaccines-13-00160"><title>3.2. Overall Breakthrough of Varicella Infection</title><p>The overall rate of breakthrough varicella infections among children born between 2015 and 2019 was 0.25%, corresponding to 1182 cases. The rate for children who received 1-dose and 2-dose VarV were 0.39% (977 cases) and 0.10% (205 cases), respectively. Specifically, the breakthrough varicella infection rates for 1-dose recipients by year of birth from 2015 to 2019 were as follows: 0.52%, 0.36%, 0.35%, 0.46% and 0.26%. In contrast, the rates for 2-dose recipients were 0.23%, 0.16%, 0.06%, 0.03% and 0.01% (<xref rid="vaccines-13-00160-f002" ref-type="fig">Figure 2</xref>). In each year of birth, the 1-dose vaccinated children had a significantly higher percentage of varicella infection than the 2-dose vaccinated children (<italic toggle="yes">p</italic> &#x0003c; 0.0001). Furthermore, the infection rates for both 1-dose and 2-dose vaccinated children demonstrated a declining trend (<xref rid="vaccines-13-00160-f002" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec3dot3-vaccines-13-00160"><title>3.3. Comparison of Basic Characteristics</title><p>The proportion of breakthrough cases following 1-dose from 2016 to 2023 was recorded at 0.82%, 7.68%, 19.24%, 22.11%, 14.43%, 22.00%, 9.52% and 4.20%. In contrast, the proportion of breakthrough cases following two doses between 2019 and 2023 was 4.39%, 8.78%, 28.29%, 22.44% and 36.10%. The average ages of onset for breakthrough cases with 1-dose and 2-dose vaccination were 2.13 &#x000b1; 0.99 years and 5.52 &#x000b1; 1.18 years, respectively (<italic toggle="yes">p</italic> &#x0003c; 0.0001). The distribution of breakthrough cases by gender for the 1-dose vaccination was 59.06% male and 40.94% female, while for the 2-dose vaccination, it was 64.44% male and 37.56% female. Statistically significant differences were observed in the year of onset, age and location between breakthrough cases associated with 1-dose vaccination and those associated with 2-dose vaccination (all <italic toggle="yes">p</italic> &#x0003c; 0.05) (<xref rid="vaccines-13-00160-t001" ref-type="table">Table 1</xref>).</p><p>The incidence of breakthrough varicella cases among children born between 2015 and 2019 varied monthly, with reported cases ranging from 56 to 167. Specifically, the number of breakthrough cases among those who received one dose ranged from 46 to 149, while those who received two doses ranged from 10 to 30. The proportion of breakthrough cases for 1-dose and 2-dose recipients from September to December was 50.05% and 47.80%, respectively (<xref rid="vaccines-13-00160-f003" ref-type="fig">Figure 3</xref>).</p></sec><sec id="sec3dot4-vaccines-13-00160"><title>3.4. Time Interval Between VarV Vaccination and Onset</title><p>The longest interval observed between vaccination and the onset of 1182 breakthrough varicella cases was 80.49 months, while the shortest interval was 1.49 months, with a median duration of 22.70 months. For breakthrough varicella cases following 1-dose and 2-dose vaccinations, the intervals between vaccination and onset were recorded as 1.49 to 80.49 months and 1.56 to 56.69 months, respectively. The median intervals were 23.79 months and 18.35 months. The cumulative breakthrough infection rate in 1-dose vaccination increased rapidly to 0.36 within the first 36 months, followed by a gradual increase. In contrast, the 2-dose group exhibited a slow increase to 0.08 within 36 months, after which it stabilized (<xref rid="vaccines-13-00160-f004" ref-type="fig">Figure 4</xref>).</p></sec><sec id="sec3dot5-vaccines-13-00160"><title>3.5. Vaccine Effectiveness</title><p>The total varicella vaccine effectiveness (VE) of 1-dose VarV was 85% (95% confidence interval: 84&#x02013;86) and of 2-dose VarV was 96% (95% confidence interval: 96&#x02013;97). The VE of 1-dose VarV in the five birth cohorts was lower than that of 2-dose VarV, with a minimum value of 73% and a maximum value of 91%. The VE of 2-dose VarV increased year by year, with a minimum of 93% and a maximum of 99%. The incremental varicella vaccine effectiveness (VE) of 2-dose varicella vaccination regimen, in comparison to the 1-dose regimen, exhibited an increase for individuals born between 2015 and 2019, rising from 56% (95% confidence interval: 44.43&#x02013;65.87) to 95% (95% confidence interval: 88.16&#x02013;98.02). Furthermore, the overall incremental VE of the 2-dose regimen relative to the 1-dose regimen was determined to be 75% (95% confidence interval: 71.49&#x02013;78.91). Specifically, the incremental VE for individuals born in 2018 and 2019 was found to be 94% (95% confidence interval: 89.00&#x02013;96.56) and 95% (95% confidence interval: 88.16&#x02013;98.02), respectively (<xref rid="vaccines-13-00160-t002" ref-type="table">Table 2</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00160"><title>4. Discussion</title><p>The results indicated that the cumulative incidence of breakthrough varicella cases among children born in the Pudong New Area of Shanghai from 2015 to 2019, during the period from 2016 to 2023, was 0.25%. Furthermore, the incidence of breakthrough varicella cases in children who received one or two doses of the varicella vaccine (VarV) increased with the duration of VarV vaccination. The findings demonstrated that the 2-dose VarV was significantly more effective than the 1-dose VarV in preventing varicella infection, with an incremental VE of 75% (confidence interval: 71.49&#x02013;78.91). Additionally, the incremental VE of 2-dose VarV among children born in 2018 and 2019 was 94% (confidence interval: 89.00&#x02013;96.56) and 95% (confidence interval: 88.16&#x02013;98.02), respectively.</p><p>The incidence of breakthrough varicella infections among individuals born between 2015 and 2019 has demonstrated a decline, decreasing from 0.52% to 0.26% for those receiving a single dose of the varicella vaccine, and from 0.23% to 0.01% for those receiving two doses. Previous studies [<xref rid="B20-vaccines-13-00160" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-13-00160" ref-type="bibr">21</xref>] have indicated that breakthrough varicella cases can occur following both 1-dose and 2-dose VarV, with the incidence of breakthrough varicella cases being lower in individuals who received two doses compared to those who received one dose [<xref rid="B22-vaccines-13-00160" ref-type="bibr">22</xref>]. This finding aligns with the results of current study, which further suggests that the protective efficacy of 2-dose VarV is superior to that of 1-dose VarV. The protective effect of the varicella vaccine diminishes over time, eventually leading to breakthrough varicella cases. Research conducted in the United States has demonstrated that varicella outbreaks and breakthrough varicella cases still occur following one dose of VarV vaccination, and indicated that even with high coverage of VarV vaccination, the protective effect was approximately 85%, which was insufficient to prevent varicella outbreaks in educational settings such as schools and kindergartens [<xref rid="B23-vaccines-13-00160" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-13-00160" ref-type="bibr">24</xref>]. Consequently, it is imperative to revise the vaccination strategy for varicella in China.</p><p>The results indicated that the vaccine effectiveness (VE) of 1-dose VarV ranged from 73% (66&#x02013;77%) to 91% (89&#x02013;92%), with a mean effectiveness of 84.2%, which is consistent with similar studies conducted in China [<xref rid="B4-vaccines-13-00160" ref-type="bibr">4</xref>]. This study was performed in a community-based environment characterized by high natural exposure and transmission rates of varicella, where exogenous exposure may contribute to a prolonged enhancement of immunity in vaccinated individuals, potentially leading to an overestimation of the efficacy of one dose of vaccination [<xref rid="B25-vaccines-13-00160" ref-type="bibr">25</xref>]. In contrast, the VE for 2-dose VarV ranged from 93% (92&#x02013;95%) to 99% (98&#x02013;100%) with a mean effectiveness of 96.8%. These results algin with findings from a study conducted in the United States [<xref rid="B26-vaccines-13-00160" ref-type="bibr">26</xref>], where the one-dose VarV vaccination program was initiated in 1996, followed by the introduction of the two-dose VarV vaccination program in 2006. The first dose was administered at 12&#x02013;15 months of age, while the second dose was given at 4&#x02013;6 years of age [<xref rid="B27-vaccines-13-00160" ref-type="bibr">27</xref>]. The protective effect of the two-dose VarV strategy in the United States was reported to be between 94% and 98% [<xref rid="B23-vaccines-13-00160" ref-type="bibr">23</xref>]. Additionally, a study by Kauffmann and colleagues further corroborated that the two-dose VarV strategy demonstrated greater effectiveness compared to the one-dose VarV strategy in Germany [<xref rid="B28-vaccines-13-00160" ref-type="bibr">28</xref>]. An Italian study showed [<xref rid="B29-vaccines-13-00160" ref-type="bibr">29</xref>] that the most effective strategy was two doses of the varicella vaccine, which caused a 66% reduction in varicella cases and a 30% reduction in varicella-related deaths compared to without VarV immunization strategy, which showed that varicella vaccination played a significant role in reducing varicella incidence and social costs, supporting the Italian policy of varicella vaccine into the NIP.</p><p>This study indicated that the majority of breakthrough cases with 1-dose and 2-dose vaccinations occurred in males. It is possible that boys have greater opportunities for exposure to the virus. However, some research has demonstrated that there is no significant gender difference in varicella infection rates [<xref rid="B30-vaccines-13-00160" ref-type="bibr">30</xref>], while other studies have reported a higher incidence of varicella in females compared to males [<xref rid="B7-vaccines-13-00160" ref-type="bibr">7</xref>]. These discrepancies may be attributed to varying exposure risks associated with different genders in distinct geographical regions. Additionally, the existing literature suggests that treatment bias and sample collection methods may also contribute to observed gender differences between males [<xref rid="B31-vaccines-13-00160" ref-type="bibr">31</xref>] and females, as varicella zoster virus is considered a non-gender-specific disease [<xref rid="B32-vaccines-13-00160" ref-type="bibr">32</xref>].</p><p>The incidence of breakthrough varicella cases exhibits distinct seasonal patterns, with elevated rates observed from April to June and September to December [<xref rid="B33-vaccines-13-00160" ref-type="bibr">33</xref>]. The incidence of breakthrough varicella cases among individuals who received 1-dose and 2-dose VarV was significantly higher during these months, accounting for 50.05% and 47.80%, respectively. The period from April to June and September to December coincide with the academic calendar, during which susceptible populations congregate indoors, thereby increasing the risk of infection. This phenomenon may be attributed to the clustering characteristics of susceptible individuals. Furthermore, related research indicates that varicella is more likely to manifest in winter and spring within warm tropical regions, as the climatic conditions during these seasons facilitate the proliferation and transmission of the varicella virus [<xref rid="B34-vaccines-13-00160" ref-type="bibr">34</xref>].</p><p>Several studies have indicated that the median time interval between varicella vaccination and the occurrence of breakthrough varicella cases is approximately 7 years, with the shortest interval reported being 1.5 years [<xref rid="B20-vaccines-13-00160" ref-type="bibr">20</xref>]. These intervals are notably longer than the findings of the present study, which may be attributable to factors such as the age at which vaccination was administered and the duration of observation for the study participants. Additionally, another investigation revealed that the time interval between the administration of 1-dose VarV and the onset of varicella was 2.3 years [<xref rid="B35-vaccines-13-00160" ref-type="bibr">35</xref>], a finding that aligns closely with the results of the current study. In this study, we observed that the cumulative reported incidence of breakthrough varicella cases following one dose of VarV increased rapidly to 0.36 within the first 36 months, subsequently exhibiting a gradual disease. In contrast, the incidence following 2-dose VarV increased slowly to 0.08 within 36 months and then stabilized. Notably, the cumulative breakthrough infection rate in 1-dose VarV was significantly higher than that in 2-dose, indicating that the 2-dose was much more effective in delaying the onset of breakthrough varicella cases compared to the 1-dose VarV. These findings suggest that administering two doses of VarV could potentially reduce the incidence of breakthrough varicella cases, which aligns with previous conclusions indicating that the protective effect of the vaccination in two doses is superior to that of the 1-dose vaccination [<xref rid="B21-vaccines-13-00160" ref-type="bibr">21</xref>,<xref rid="B36-vaccines-13-00160" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-13-00160" ref-type="bibr">37</xref>]. Furthermore, the incremental VE of 56% and 57% for 2-dose VarV in individuals born in 2015 and 2016 was considerably lower than the incremental VE of 94% and 95% observed in those born in 2018 and 2019. This discrepancy may be partially attributed to the waning of immunity or an increased risk of exposure among older children [<xref rid="B38-vaccines-13-00160" ref-type="bibr">38</xref>] (those born in 2015&#x02013;2016 were 7&#x02013;8 years old at the end of 2023), which also suggests a trend of decreasing VE over time.</p><p>This study acknowledges several limitations. The incidence of varicella breakthrough cases across various birth cohorts was only monitored until the conclusion of 2023. Consequently, the cumulative rates at different intervals post-vaccination were not comprehensively documented. Additionally, some breakthrough varicella cases exhibited varying clinical symptoms. Mild or atypical infections may not prompt individuals to seek medical attention, which could result in an underestimation of the incidence of breakthrough varicella cases.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00160"><title>5. Conclusions</title><p>In conclusion, the incidence of breakthrough varicella infections among individuals who received 2-dose vaccination was significantly lower than that observed in those who received one dose of the varicella vaccine. Additionally, the effectiveness of the 2-dose vaccine exceeded 90% in comparison to the 1-dose vaccine, indicating that the 2-dose vaccination schedule provides substantially greater protection than the 1-dose vaccination schedule. Therefore, it is recommended that the expanded 2-dose regimen of the varicella vaccine be advocated for the prevention of varicella infections among children in China.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>M.L. and C.X. designed the study protocol; T.Y., P.D. and C.X. collected the data; M.L. and T.Y. completed data analysis and wrote the original draft; L.Y. and C.X. were responsible for funding, resource, supervision and writing-reviewing and editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable. Case data were collected as part of a routine work and analyzed to guide public health programming.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Restrictions apply to the availability of these data, which were collected from the Shanghai Pudong and National Information System. Data are available from the authors with permission from the Shanghai Pudong New Area Center for Disease Control and Prevention.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Chinese Center for Disease Control and Prevention. The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00160"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gershon</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?</article-title><source>J. Infect.</source><year>2017</year><volume>74</volume><issue>(Suppl. S1)</issue><fpage>S27</fpage><lpage>S33</lpage><pub-id pub-id-type="doi">10.1016/S0163-4453(17)30188-3</pub-id><pub-id pub-id-type="pmid">28646959</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00160"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiu</surname><given-names>S.</given-names></name>
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Yang</surname><given-names>M.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Varicella vaccine effectiveness evaluation in Wuxi, China: A retrospective cohort study</article-title><source>Epidemiol. Infect.</source><year>2024</year><volume>152</volume><fpage>e105</fpage><pub-id pub-id-type="doi">10.1017/S095026882400102X</pub-id><pub-id pub-id-type="pmid">39344904</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00160"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>P.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Xiao</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Guan</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
</person-group><article-title>Effectiveness of one-dose versus two-dose varicella vaccine in children in Qingdao, China: A matched case-control study</article-title><source>Hum. Vaccin. Immunother.</source><year>2021</year><volume>17</volume><fpage>5311</fpage><lpage>5315</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.1982281</pub-id><pub-id pub-id-type="pmid">34623220</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00160"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Du</surname><given-names>J.</given-names></name>
<name><surname>Cai</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Che</surname><given-names>X.</given-names></name>
<name><surname>Gu</surname><given-names>W.</given-names></name>
<name><surname>Jiang</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Epidemiology of varicella and effectiveness of varicella vaccine in Hangzhou, China, 2019</article-title><source>Hum. Vaccin. Immunother.</source><year>2021</year><volume>17</volume><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1769395</pub-id><pub-id pub-id-type="pmid">32574100</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00160"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawamura</surname><given-names>Y.</given-names></name>
<name><surname>Hattori</surname><given-names>F.</given-names></name>
<name><surname>Higashimoto</surname><given-names>Y.</given-names></name>
<name><surname>Kozawa</surname><given-names>K.</given-names></name>
<name><surname>Yoshikawa</surname><given-names>T.</given-names></name>
</person-group><article-title>Evaluation of varicella vaccine effectiveness during outbreaks in schools or nurseries by cross-sectional study</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>2901</fpage><lpage>2905</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.04.009</pub-id><pub-id pub-id-type="pmid">33895017</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00160"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Varicella and herpes zoster vaccines: WHO position paper, June 2014</article-title><source>Wkly. Epidemiol. Rec.</source><year>2014</year><volume>89</volume><fpage>265</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">24983077</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00160"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Jiang</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Lin</surname><given-names>S.</given-names></name>
</person-group><article-title>The global disease burden of varicella-zoster virus infection from 1990 to 2019</article-title><source>J. Med. Virol.</source><year>2022</year><volume>94</volume><fpage>2736</fpage><lpage>2746</lpage><pub-id pub-id-type="doi">10.1002/jmv.27538</pub-id><pub-id pub-id-type="pmid">34936114</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00160"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lieu</surname><given-names>T.A.</given-names></name>
<name><surname>Cochi</surname><given-names>S.L.</given-names></name>
<name><surname>Black</surname><given-names>S.B.</given-names></name>
<name><surname>Halloran</surname><given-names>M.E.</given-names></name>
<name><surname>Shinefield</surname><given-names>H.R.</given-names></name>
<name><surname>Holmes</surname><given-names>S.J.</given-names></name>
<name><surname>Wharton</surname><given-names>M.</given-names></name>
<name><surname>Washington</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Cost-effectiveness of a routine varicella vaccination program for US children</article-title><source>JAMA</source><year>1994</year><volume>271</volume><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1001/jama.1994.03510290057037</pub-id><pub-id pub-id-type="pmid">8283587</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00160"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lenne</surname><given-names>X.</given-names></name>
<name><surname>Diez Domingo</surname><given-names>J.</given-names></name>
<name><surname>Gil</surname><given-names>A.</given-names></name>
<name><surname>Ridao</surname><given-names>M.</given-names></name>
<name><surname>Lluch</surname><given-names>J.A.</given-names></name>
<name><surname>Dervaux</surname><given-names>B.</given-names></name>
</person-group><article-title>Economic evaluation of varicella vaccination in Spain: Results from a dynamic model</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>6980</fpage><lpage>6989</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.04.051</pub-id><pub-id pub-id-type="pmid">16860909</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00160"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pawaskar</surname><given-names>M.</given-names></name>
<name><surname>Meroc</surname><given-names>E.</given-names></name>
<name><surname>Samant</surname><given-names>S.</given-names></name>
<name><surname>Flem</surname><given-names>E.</given-names></name>
<name><surname>Bencina</surname><given-names>G.</given-names></name>
<name><surname>Riera-Montes</surname><given-names>M.</given-names></name>
<name><surname>Heininger</surname><given-names>U.</given-names></name>
</person-group><article-title>Economic burden of varicella in Europe in the absence of universal varicella vaccination</article-title><source>BMC Public Health</source><year>2021</year><volume>21</volume><elocation-id>2312</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-021-12343-x</pub-id><pub-id pub-id-type="pmid">34930179</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00160"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zha</surname><given-names>W.T.</given-names></name>
<name><surname>Pang</surname><given-names>F.R.</given-names></name>
<name><surname>Zhou</surname><given-names>N.</given-names></name>
<name><surname>Wu</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Du</surname><given-names>Y.B.</given-names></name>
<name><surname>Hong</surname><given-names>X.Q.</given-names></name>
<name><surname>Lv</surname><given-names>Y.</given-names></name>
</person-group><article-title>Research about the optimal strategies for prevention and control of varicella outbreak in a school in a central city of China: Based on an SEIR dynamic model</article-title><source>Epidemiol. Infect.</source><year>2020</year><volume>148</volume><fpage>e56</fpage><pub-id pub-id-type="doi">10.1017/S0950268819002188</pub-id><pub-id pub-id-type="pmid">32178752</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00160"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leung</surname><given-names>J.</given-names></name>
<name><surname>Harpaz</surname><given-names>R.</given-names></name>
</person-group><article-title>Impact of the Maturing Varicella Vaccination Program on Varicella and Related Outcomes in the United States: 1994-2012</article-title><source>J. Pediatr. Infect. Dis. Soc.</source><year>2016</year><volume>5</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1093/jpids/piv044</pub-id></element-citation></ref><ref id="B13-vaccines-13-00160"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scotta</surname><given-names>M.C.</given-names></name>
<name><surname>Paternina-de la Ossa</surname><given-names>R.</given-names></name>
<name><surname>Lumertz</surname><given-names>M.S.</given-names></name>
<name><surname>Jones</surname><given-names>M.H.</given-names></name>
<name><surname>Mattiello</surname><given-names>R.</given-names></name>
<name><surname>Pinto</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Early impact of universal varicella vaccination on childhood varicella and herpes zoster hospitalizations in Brazil</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>280</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.11.057</pub-id><pub-id pub-id-type="pmid">29198917</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00160"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>A.</given-names></name>
<name><surname>Feng</surname><given-names>Z.</given-names></name>
<name><surname>Seward</surname><given-names>J.F.</given-names></name>
<name><surname>Bialek</surname><given-names>S.R.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
</person-group><article-title>Single-dose varicella vaccine effectiveness in school settings in China</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>3834</fpage><lpage>3838</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.06.075</pub-id><pub-id pub-id-type="pmid">23845816</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00160"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pan</surname><given-names>X.</given-names></name>
<name><surname>Shu</surname><given-names>M.</given-names></name>
<name><surname>Ma</surname><given-names>R.</given-names></name>
<name><surname>Fang</surname><given-names>T.</given-names></name>
<name><surname>Dong</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>G.</given-names></name>
</person-group><article-title>Varicella breakthrough infection and effectiveness of 2-dose varicella vaccine in China</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>5665</fpage><lpage>5670</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.05.025</pub-id><pub-id pub-id-type="pmid">30104113</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00160"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaves</surname><given-names>S.S.</given-names></name>
<name><surname>Gargiullo</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>J.X.</given-names></name>
<name><surname>Civen</surname><given-names>R.</given-names></name>
<name><surname>Guris</surname><given-names>D.</given-names></name>
<name><surname>Mascola</surname><given-names>L.</given-names></name>
<name><surname>Seward</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Loss of vaccine-induced immunity to varicella over time</article-title><source>N. Engl. J. Med.</source><year>2007</year><volume>356</volume><fpage>1121</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa064040</pub-id><pub-id pub-id-type="pmid">17360990</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00160"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leung</surname><given-names>J.</given-names></name>
<name><surname>Broder</surname><given-names>K.R.</given-names></name>
<name><surname>Marin</surname><given-names>M.</given-names></name>
</person-group><article-title>Severe varicella in persons vaccinated with varicella vaccine (breakthrough varicella): A systematic literature review</article-title><source>Expert. Rev. Vaccines</source><year>2017</year><volume>16</volume><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1080/14760584.2017.1294069</pub-id><pub-id pub-id-type="pmid">28276305</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00160"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suo</surname><given-names>L.</given-names></name>
<name><surname>Lu</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Pang</surname><given-names>X.</given-names></name>
<name><surname>Marin</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
</person-group><article-title>Varicella outbreak in a highly-vaccinated school population in Beijing, China during the voluntary two-dose era</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>4368</fpage><lpage>4373</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.06.065</pub-id><pub-id pub-id-type="pmid">28684165</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00160"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Q.S.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>J.Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.F.</given-names></name>
<name><surname>Zhou</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Sha</surname><given-names>J.D.</given-names></name>
<name><surname>Xuan</surname><given-names>Z.L.</given-names></name>
<name><surname>Zhang</surname><given-names>L.W.</given-names></name>
<name><surname>Yan</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Varicella outbreak trends in school settings during the voluntary single-dose vaccine era from 2006 to 2017 in Shanghai, China</article-title><source>Int. J. Infect. Dis.</source><year>2019</year><volume>89</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2019.09.009</pub-id><pub-id pub-id-type="pmid">31521857</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00160"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Yuan</surname><given-names>L.</given-names></name>
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<name><surname>Fan</surname><given-names>J.</given-names></name>
<name><surname>Jing</surname><given-names>Y.</given-names></name>
<name><surname>Meng</surname><given-names>S.</given-names></name>
</person-group><article-title>Analysis on the epidemiological characteristics of varicella and breakthrough case from 2014 to 2022 in Qingyang City</article-title><source>Hum. Vaccin. Immunother.</source><year>2023</year><volume>19</volume><fpage>2224075</fpage><pub-id pub-id-type="doi">10.1080/21645515.2023.2224075</pub-id><pub-id pub-id-type="pmid">37345683</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00160"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shu</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Ma</surname><given-names>R.</given-names></name>
<name><surname>Yang</surname><given-names>T.</given-names></name>
<name><surname>Pan</surname><given-names>X.</given-names></name>
</person-group><article-title>Long-term vaccine efficacy of a 2-dose varicella vaccine in China from 2011 to 2021: A retrospective observational study</article-title><source>Front. Public Health</source><year>2022</year><volume>10</volume><elocation-id>1039537</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2022.1039537</pub-id><pub-id pub-id-type="pmid">36424959</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00160"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>S.</given-names></name>
<name><surname>Zeng</surname><given-names>F.</given-names></name>
<name><surname>Xia</surname><given-names>L.</given-names></name>
<name><surname>He</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
</person-group><article-title>Incidence rate of breakthrough varicella observed in healthy children after 1 or 2 doses of varicella vaccine: Results from a meta-analysis</article-title><source>Am. J. Infect. Control</source><year>2018</year><volume>46</volume><fpage>e1</fpage><lpage>e7</lpage><pub-id pub-id-type="doi">10.1016/j.ajic.2017.07.029</pub-id><pub-id pub-id-type="pmid">28935482</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00160"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bonanni</surname><given-names>P.</given-names></name>
<name><surname>Zanobini</surname><given-names>P.</given-names></name>
</person-group><article-title>Universal and targeted varicella vaccination</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>11</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30358-3</pub-id><pub-id pub-id-type="pmid">32711691</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00160"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lachiewicz</surname><given-names>A.M.</given-names></name>
<name><surname>Srinivas</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Varicella-zoster virus post-exposure management and prophylaxis: A review</article-title><source>Prev. Med. Rep.</source><year>2019</year><volume>16</volume><fpage>101016</fpage><pub-id pub-id-type="doi">10.1016/j.pmedr.2019.101016</pub-id><pub-id pub-id-type="pmid">31890472</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00160"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Ni</surname><given-names>J.</given-names></name>
</person-group><article-title>Effectiveness, immunogenicity and safety of one vs. two-dose varicella vaccination: A meta-analysis</article-title><source>Expert Rev. Vaccines</source><year>2018</year><volume>17</volume><fpage>351</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1080/14760584.2018.1433999</pub-id><pub-id pub-id-type="pmid">29388450</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00160"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shapiro</surname><given-names>E.D.</given-names></name>
<name><surname>Vazquez</surname><given-names>M.</given-names></name>
<name><surname>Esposito</surname><given-names>D.</given-names></name>
<name><surname>Holabird</surname><given-names>N.</given-names></name>
<name><surname>Steinberg</surname><given-names>S.P.</given-names></name>
<name><surname>Dziura</surname><given-names>J.</given-names></name>
<name><surname>LaRussa</surname><given-names>P.S.</given-names></name>
<name><surname>Gershon</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Effectiveness of 2 doses of varicella vaccine in children</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>203</volume><fpage>312</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiq052</pub-id><pub-id pub-id-type="pmid">21208922</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00160"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopez</surname><given-names>A.S.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Marin</surname><given-names>M.</given-names></name>
</person-group><article-title>Epidemiology of Varicella During the 2-Dose Varicella Vaccination Program&#x02014;United States, 2005&#x02013;2014</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2016</year><volume>65</volume><fpage>902</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6534a4</pub-id><pub-id pub-id-type="pmid">27584717</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00160"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kauffmann</surname><given-names>F.</given-names></name>
<name><surname>Bechini</surname><given-names>A.</given-names></name>
<name><surname>Bonanni</surname><given-names>P.</given-names></name>
<name><surname>Casabona</surname><given-names>G.</given-names></name>
<name><surname>Wutzler</surname><given-names>P.</given-names></name>
</person-group><article-title>Varicella vaccination in Italy and Germany&#x02014;Different routes to success: A systematic review</article-title><source>Expert. Rev. Vaccines</source><year>2020</year><volume>19</volume><fpage>843</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1080/14760584.2020.1825947</pub-id><pub-id pub-id-type="pmid">32969747</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00160"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azzari</surname><given-names>C.</given-names></name>
<name><surname>Baldo</surname><given-names>V.</given-names></name>
<name><surname>Giuffrida</surname><given-names>S.</given-names></name>
<name><surname>Gani</surname><given-names>R.</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>E.</given-names></name>
<name><surname>Alimenti</surname><given-names>C.</given-names></name>
<name><surname>Daniels</surname><given-names>V.J.</given-names></name>
<name><surname>Wolfson</surname><given-names>L.J.</given-names></name>
</person-group><article-title>The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies</article-title><source>Clin. Outcomes Res.</source><year>2020</year><volume>12</volume><fpage>273</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.2147/CEOR.S229685</pub-id></element-citation></ref><ref id="B30-vaccines-13-00160"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iftimi</surname><given-names>A.</given-names></name>
<name><surname>Montes</surname><given-names>F.</given-names></name>
<name><surname>Santiyan</surname><given-names>A.M.</given-names></name>
<name><surname>Martinez-Ruiz</surname><given-names>F.</given-names></name>
</person-group><article-title>Space-time airborne disease mapping applied to detect specific behaviour of varicella in Valencia, Spain</article-title><source>Spat. Spatiotemporal Epidemiol.</source><year>2015</year><volume>14&#x02013;15</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.sste.2015.07.001</pub-id></element-citation></ref><ref id="B31-vaccines-13-00160"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koshy</surname><given-names>E.</given-names></name>
<name><surname>Mengting</surname><given-names>L.</given-names></name>
<name><surname>Kumar</surname><given-names>H.</given-names></name>
<name><surname>Jianbo</surname><given-names>W.</given-names></name>
</person-group><article-title>Epidemiology, treatment and prevention of herpes zoster: A comprehensive review</article-title><source>Indian. J. Dermatol. Venereol. Leprol.</source><year>2018</year><volume>84</volume><fpage>251</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.4103/ijdvl.IJDVL_1021_16</pub-id><pub-id pub-id-type="pmid">29516900</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00160"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>R.W.</given-names></name>
<name><surname>Wasner</surname><given-names>G.</given-names></name>
<name><surname>Saddier</surname><given-names>P.</given-names></name>
<name><surname>Baron</surname><given-names>R.</given-names></name>
</person-group><article-title>Herpes zoster and postherpetic neuralgia: Optimizing management in the elderly patient</article-title><source>Drugs Aging</source><year>2008</year><volume>25</volume><fpage>991</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.2165/0002512-200825120-00002</pub-id><pub-id pub-id-type="pmid">19021299</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00160"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sumi</surname><given-names>A.</given-names></name>
</person-group><article-title>Role of temperature in reported chickenpox cases in northern European countries: Denmark and Finland</article-title><source>BMC Res. Notes</source><year>2018</year><volume>11</volume><elocation-id>377</elocation-id><pub-id pub-id-type="doi">10.1186/s13104-018-3497-0</pub-id><pub-id pub-id-type="pmid">29895325</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00160"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gershon</surname><given-names>A.A.</given-names></name>
<name><surname>Gershon</surname><given-names>M.D.</given-names></name>
<name><surname>Breuer</surname><given-names>J.</given-names></name>
<name><surname>Levin</surname><given-names>M.J.</given-names></name>
<name><surname>Oaklander</surname><given-names>A.L.</given-names></name>
<name><surname>Griffiths</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Advances in the understanding of the pathogenesis and epidemiology of herpes zoster</article-title><source>J. Clin. Virol.</source><year>2010</year><volume>48</volume><issue>(Suppl. S1)</issue><fpage>S2</fpage><lpage>S7</lpage><pub-id pub-id-type="doi">10.1016/S1386-6532(10)70002-0</pub-id><pub-id pub-id-type="pmid">20510263</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00160"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>W.C.</given-names></name>
<name><surname>Huang</surname><given-names>L.M.</given-names></name>
<name><surname>Chang</surname><given-names>I.S.</given-names></name>
<name><surname>Tsai</surname><given-names>F.Y.</given-names></name>
<name><surname>Chang</surname><given-names>L.Y.</given-names></name>
</person-group><article-title>Varicella breakthrough infection and vaccine effectiveness in Taiwan</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>2756</fpage><lpage>2760</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.092</pub-id><pub-id pub-id-type="pmid">21315697</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00160"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shapiro</surname><given-names>E.D.</given-names></name>
<name><surname>Marin</surname><given-names>M.</given-names></name>
</person-group><article-title>The Effectiveness of Varicella Vaccine: 25 Years of Postlicensure Experience in the United States</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>226</volume><fpage>S425</fpage><lpage>S430</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac299</pub-id><pub-id pub-id-type="pmid">36265844</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00160"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>L.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Yao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Impact of Varicella Immunization and Public Health and Social Measures on Varicella Incidence: Insights from Surveillance Data in Shanghai, 2013&#x02013;2022</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1674</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11111674</pub-id><pub-id pub-id-type="pmid">38006006</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00160"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bonanni</surname><given-names>P.</given-names></name>
<name><surname>Gershon</surname><given-names>A.</given-names></name>
<name><surname>Gershon</surname><given-names>M.</given-names></name>
<name><surname>Kulcsar</surname><given-names>A.</given-names></name>
<name><surname>Papaevangelou</surname><given-names>V.</given-names></name>
<name><surname>Rentier</surname><given-names>B.</given-names></name>
<name><surname>Sadzot-Delvaux</surname><given-names>C.</given-names></name>
<name><surname>Usonis</surname><given-names>V.</given-names></name>
<name><surname>Vesikari</surname><given-names>T.</given-names></name>
<name><surname>Weil-Olivier</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Primary versus secondary failure after varicella vaccination: Implications for interval between 2 doses</article-title><source>Pediatr. Infect. Dis. J.</source><year>2013</year><volume>32</volume><fpage>e305</fpage><lpage>e313</lpage><pub-id pub-id-type="doi">10.1097/INF.0b013e31828b7def</pub-id><pub-id pub-id-type="pmid">23838789</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00160-f001"><label>Figure 1</label><caption><p>Flowchart for breakthrough varicella cases inclusion.</p></caption><graphic xlink:href="vaccines-13-00160-g001" position="float"/></fig><fig position="float" id="vaccines-13-00160-f002"><label>Figure 2</label><caption><p>The number of breakthrough varicella cases and breakthrough infection rate among different years of birth.</p></caption><graphic xlink:href="vaccines-13-00160-g002" position="float"/></fig><fig position="float" id="vaccines-13-00160-f003"><label>Figure 3</label><caption><p>The number of breakthrough varicella cases among the children in different months of onset.</p></caption><graphic xlink:href="vaccines-13-00160-g003" position="float"/></fig><fig position="float" id="vaccines-13-00160-f004"><label>Figure 4</label><caption><p>The time interval between VarV vaccination and onset among the children birth of 2015&#x02013;2019. The dashed red line/arrow represents an inflection point, the 36th month after vaccination. After this point, the trend of the breakthrough infection rate has remained stable.</p></caption><graphic xlink:href="vaccines-13-00160-g004" position="float"/></fig><table-wrap position="float" id="vaccines-13-00160-t001"><object-id pub-id-type="pii">vaccines-13-00160-t001_Table 1</object-id><label>Table 1</label><caption><p>Comparison of basic characteristics between breakthrough cases with 1-dose and 2-dose varicella vaccination among children born between 2015 and 2019.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Basic Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Breakthrough Cases with 1-Dose (N = 977)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Breakthrough Cases with 2-Dose (N = 205)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Year of onset</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">p</italic> &#x0003c; 0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (0.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" rowspan="1" colspan="1">75 (7.68)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" rowspan="1" colspan="1">188 (19.24)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" rowspan="1" colspan="1">216 (22.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (4.39)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" rowspan="1" colspan="1">141 (14.43)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (8.78)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" rowspan="1" colspan="1">215 (22.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">58 (28.29)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" rowspan="1" colspan="1">93 (9.52)</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (22.44)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (4.20)</td><td align="center" valign="middle" rowspan="1" colspan="1">74 (36.10)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age </td><td align="center" valign="middle" rowspan="1" colspan="1">2.13 &#x000b1; 0.99</td><td align="center" valign="middle" rowspan="1" colspan="1">5.52 &#x000b1; 1.18</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">p</italic> &#x0003c; 0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gender</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.207</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">577 (59.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">128 (64.44)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">400 (40.94)</td><td align="center" valign="middle" rowspan="1" colspan="1">77 (37.56)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Location </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Local</td><td align="center" valign="middle" rowspan="1" colspan="1">773 (79.12)</td><td align="center" valign="middle" rowspan="1" colspan="1">174 (84.88)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inward</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">204 (20.88)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 (15.12)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00160-t002"><object-id pub-id-type="pii">vaccines-13-00160-t002_Table 2</object-id><label>Table 2</label><caption><p>The overall and incremental vaccine effectiveness of 2-dose varicella vaccination among the children born between 2015 and 2019.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year of Birth</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccination Status</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Case</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">RR (95% CI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">VE % (95% CI)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" rowspan="1" colspan="1">Unvaccinated</td><td align="center" valign="middle" rowspan="1" colspan="1">8511</td><td align="center" valign="middle" rowspan="1" colspan="1">288</td><td align="center" valign="middle" rowspan="1" colspan="1">Reference </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">44,381</td><td align="center" valign="middle" rowspan="1" colspan="1">230</td><td align="center" valign="middle" rowspan="1" colspan="1">0.15 (0.13&#x02013;0.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">85 (82&#x02013;87)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">39,877</td><td align="center" valign="middle" rowspan="1" colspan="1">90</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07 (0.05&#x02013;0.08)</td><td align="center" valign="middle" rowspan="1" colspan="1">93 (92&#x02013;95)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Incremental *</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.44 (0.34&#x02013;0.56)</td><td align="center" valign="middle" rowspan="1" colspan="1">56 (44&#x02013;66)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" rowspan="1" colspan="1">Unvaccinated</td><td align="center" valign="middle" rowspan="1" colspan="1">11,092</td><td align="center" valign="middle" rowspan="1" colspan="1">423</td><td align="center" valign="middle" rowspan="1" colspan="1">Reference </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">60,252</td><td align="center" valign="middle" rowspan="1" colspan="1">218</td><td align="center" valign="middle" rowspan="1" colspan="1">0.09 (0.08&#x02013;0.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">91 (89&#x02013;92)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">41,587</td><td align="center" valign="middle" rowspan="1" colspan="1">65</td><td align="center" valign="middle" rowspan="1" colspan="1">0.04 (0.03&#x02013;0.05)</td><td align="center" valign="middle" rowspan="1" colspan="1">96 (95&#x02013;97)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Incremental *</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.43 (0.32&#x02013;0.57)</td><td align="center" valign="middle" rowspan="1" colspan="1">57 (43&#x02013;67)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" rowspan="1" colspan="1">Unvaccinated</td><td align="center" valign="middle" rowspan="1" colspan="1">10,410</td><td align="center" valign="middle" rowspan="1" colspan="1">301</td><td align="center" valign="middle" rowspan="1" colspan="1">Reference </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">53,828</td><td align="center" valign="middle" rowspan="1" colspan="1">191</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12 (0.10&#x02013;0.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">88 (85&#x02013;90)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">51,484</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.02 (0.02&#x02013;0.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">98 (97&#x02013;98)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Incremental *</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.18 (0.12&#x02013;0.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">82 (74&#x02013;88)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" rowspan="1" colspan="1">Unvaccinated</td><td align="center" valign="middle" rowspan="1" colspan="1">12,557</td><td align="center" valign="middle" rowspan="1" colspan="1">205</td><td align="center" valign="middle" rowspan="1" colspan="1">Reference </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">48,578</td><td align="center" valign="middle" rowspan="1" colspan="1">222</td><td align="center" valign="middle" rowspan="1" colspan="1">0.27 (0.23&#x02013;0.34)</td><td align="center" valign="middle" rowspan="1" colspan="1">73 (66&#x02013;77)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">42,665</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.02 (0.01&#x02013;0.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">98 (97&#x02013;99)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Incremental *</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06 (0.03&#x02013;0.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">94 (89&#x02013;97)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" rowspan="1" colspan="1">Unvaccinated</td><td align="center" valign="middle" rowspan="1" colspan="1">11,947</td><td align="center" valign="middle" rowspan="1" colspan="1">196</td><td align="center" valign="middle" rowspan="1" colspan="1">Reference </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">43,782</td><td align="center" valign="middle" rowspan="1" colspan="1">116</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16 (0.13&#x02013;0.20)</td><td align="center" valign="middle" rowspan="1" colspan="1">84 (80&#x02013;87)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">39,000</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01 (0.003&#x02013;0.02)</td><td align="center" valign="middle" rowspan="1" colspan="1">99 (98&#x02013;100)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Incremental *</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05 (0.02&#x02013;0.12)</td><td align="center" valign="middle" rowspan="1" colspan="1">95 (88&#x02013;98)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total </td><td align="center" valign="middle" rowspan="1" colspan="1">Unvaccinated</td><td align="center" valign="middle" rowspan="1" colspan="1">54,517</td><td align="center" valign="middle" rowspan="1" colspan="1">1413</td><td align="center" valign="middle" rowspan="1" colspan="1">Reference </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">250,821</td><td align="center" valign="middle" rowspan="1" colspan="1">977</td><td align="center" valign="middle" rowspan="1" colspan="1">0.15 (0.14&#x02013;0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">85 (84&#x02013;86)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2-dose</td><td align="center" valign="middle" rowspan="1" colspan="1">214,613</td><td align="center" valign="middle" rowspan="1" colspan="1">205</td><td align="center" valign="middle" rowspan="1" colspan="1">0.04 (0.03&#x02013;0.04)</td><td align="center" valign="middle" rowspan="1" colspan="1">96 (96&#x02013;97)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Incremental *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25 (0.21&#x02013;0.28)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75 (71&#x02013;79)</td></tr></tbody></table><table-wrap-foot><fn><p>* 1-dose recipients as reference.</p></fn></table-wrap-foot></table-wrap></floats-group></article>